(Q43655979)

25 November 2017

title

Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice (English)

1 reference

25 November 2017

Manfred Kopf

7

0 references

Martin F. Bachmann

8

object named as

Martin F Bachmann

1 reference

25 November 2017

Yu Zou

1

1 reference

25 November 2017

Ivo Sonderegger

2

1 reference

25 November 2017

Gerd Lipowsky

3

1 reference

25 November 2017

Gary T Jennings

4

1 reference

25 November 2017

Nicole Schmitz

5

1 reference

25 November 2017

Marco Landi

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

26 February 2010

1 reference

25 November 2017

1 reference

25 November 2017

volume

28

1 reference

25 November 2017

issue

18

1 reference

25 November 2017

page(s)

3192-3200

1 reference

Eosinophilic Inflammation in Asthma

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

The cellular biology of eosinophil eicosanoid formation and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Interleukin-5: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Interleukin-5 and eosinophils as therapeutic targets for asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

IL-5: biology and potential therapeutic applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: Role of eosinophils, IL-5, eotaxin, and IL-13

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Mepolizumab and exacerbations of refractory eosinophilic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

The influence of antigen organization on B cell responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

The BCL1 B lymphoma responds to IL-4, IL-5, and GM-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Antibody humanization: a case of the 'Emperor's new clothes'?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Immunogenicity of engineered antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

A vaccine against nicotine for smoking cessation: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

No audible wheezing: nuggets and conundrums from mouse asthma models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Reversal of established CD4+ type 2 T helper-mediated allergic airway inflammation and eosinophilia by therapeutic treatment with DNA vaccines limits progression towards chronic inflammation and remodelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

A role for eosinophils in airway remodelling in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.048

10.1016/J.VACCINE.2010.02.048

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference